Available online at www.sciencedirect.com



AnalyticalBiochemistry374(2008)87­98 www.elsevier.com/locate/yabio

DesignandcharacterizationofbivalentSmac-basedpeptides asantagonistsofXIAPanddevelopmentandvalidation ofafluorescencepolarizationassayforXIAPcontaining bothBIR2andBIR3domains
ZanetaNikolovska-Coleskaa,JenniferL.Meagherb,ShengJiangc, StevenA.Kawamotoa,WeiGaoa,HanYia,DongguangQina, PeterP.Rollerc,JeanneA.Stuckeyb,d,ShaomengWanga,*
Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA b Life Sciences Institute, Biophysics Research Division, University of Michigan, Ann Arbor, MI 48109, USA c Laboratory of Medicinal Chemistry, National Cancer Institute­Frederick, National Institutes of Health, Frederick, MD 21702, USA d Department of Biological Chemistry, Biophysics Research Division, University of Michigan, Ann Arbor, MI 48109, USA Received23August2007 Availableonline20November2007
a

Abstract XIAP(X-chromosome-linkedinhibitorofapoptosisprotein)isaninhibitorofapoptosisbybindingtoandinhibitionofcaspase3andcaspase-7throughitsBIR2domainandcaspase-9throughitsBIR3domain.Smac(secondmitochondria-derivedactivatorof caspases)proteinisanendogenousantagonistofXIAP.SmacformsadimerandconcurrentlybindsboththeBIR2andBIR3domains inXIAP,functioningasahighlyeY ientandpotentcellularinhibitorofXIAP.Inthisarticle,wehavedesignedandsynthesizeda c bivalentSmac-basedligand(Smac-1)anditsfluorescentlabeledanalogue(Smac-1F)andcharacterizedtheirinteractionwithdiVerent constructsofXIAP.OurstudydemonstratesthatbivalentSmac-basedligandsbindconcurrentlytoboththeBIR2andBIR3domains of XIAP and are more than 500 times more potent than the corresponding monovalent Smac-based ligands. Bivalent Smac-based ligandsalsofunctionasmuchmorepotentantagonistsofXIAPthandothecorrespondingmonovalentSmac-basedligandsincell-free functionalassays.UsingSmac-1FandXIAPcontainingbothBIR2andBIR3domains,wealsodevelopedandvalidatedanewfluorescencepolarization-basedassay.Hence,ourdesignedbivalentSmac-basedpeptidesmimicthemodeofdimericSmacproteinintheir interactionwithXIAPcontainingbothBIR2andBIR3domainsandachieveextremelyhighpotencyinbindingandfunctionalassays. OurstudyprovidesnewinsightsintothemodeofactionofbivalentSmacligandstargetingXIAPandabasisforthedesignanddevelopmentofcell-permeable,bivalentSmacmimetics. ©2008PublishedbyElsevierInc.
Keywords: BivalentSmacmimetics;XIAP;Fluorescencepolarizationbindingassay;Apoptosis

Apoptosis, or programmed cell death, is a critical cell processinnormaldevelopmentandhomeostasisofmulticellularorganisms.Inappropriateregulationofapoptosishas
 * Correspondingauthor.Fax:+17346479647. E-mail address: shaomeng@umich.edu(S.Wang). 0003-2697/$-seefrontmatter©2008PublishedbyElsevierInc. doi:10.1016/j.ab.2007.10.032

beenimplicatedinmanyhumandiseases,includingcancer [1­3].Targetingcriticalapoptosisregulatorsisanattractive therapeuticapproachforthedevelopmentofnewclassesof therapiesforthetreatmentofcancerandotherhumandiseases[1­3].

88

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

The inhibitors of apoptosis proteins (IAPs)1 are a class ofcentralapoptosisregulators[4].XIAP(X-chromosomelinked IAP) is the best-characterized IAP family member. Structurally,XIAPcontainsthreerepeatsofthebaculovirus IAP repeat (BIR) domain [4]. XIAP functions as a potent endogenous inhibitor of apoptosis by directly binding to andeVectivelyinhibitingthreemembersofthecaspasefamily of enzymes--the two eVectors (caspase-3 and caspase7)andaninitiator(caspase-9)--throughtwodiVerentBIR domains [4­9]. The second BIR domain (BIR2), together withtheimmediatelyprecedinglinkerregion,isresponsible forthebindingtoandinhibitionofcaspase-3andcaspase7,whereasthethirdBIRdomain(BIR3)isinvolvedinthe interaction with and inhibition of caspase-9 [4­7]. Consistentwithitspotentantiapoptoticfunction,XIAPiswidely expressedinhumancancerswhereitplaysacriticalrolein mediatingtheresistanceofcancercellstochemotherapeutic agents[8­11].BecauseXIAPblocksapoptosisdownstream wheremultiplesignalingpathwaysconverge,strategiestargetingXIAPmayprovetobeparticularlyeVectiveinovercoming the resistance of cancer cells to apoptosis and for thedevelopmentofanentirelynewclassofanticancerdrugs [8­11]. Smac/DIABLO(secondmitochondria-derivedactivator ofcaspasesordirectIAPbindingproteinwithlowpI)has been identified as an endogenous IAP antagonist that is releasedfrommitochondriaintothecytosolinresponseto apoptoticstimuli[12,13].ThematureformofSmachasfour exposedN-terminalresidues,AVPI(namedtheIAPbindingmotif[14]),whichmediatesthebindingofSmactoboth theBIR2andBIR3domainsofXIAPandforitsinhibition ofXIAP[15].TheX-raycrystalstructureofSmacprotein complexed with XIAP BIR3 shows that Smac functions inadimericform[16].ItwasshownthatthematureSmac protein interacts with an XIAP construct containing both BIR2andBIR3domainswithasubnanomoardissociation l constant by the concurrent interaction of the Smac dimer withtheBIR2andBIR3domainsofasingleXIAPmolecule [17].Inthismanner,thematureSmacproteinfunctionsasa highlyeY ientandpotentinhibitorofXIAPthroughbindc ingtobothBIR2andBIR3domainsinXIAPandremoval
 1 Abbreviations used:IAP,inhibitorofapoptosisprotein;XIAP,X-chromosome-linkedIAP;BIR,baculovirusIAPrepeat;Smac,secondmitochondria-derived activator of caspases; DIABLO, direct IAP binding protein with low pI; FP, fluorescence polarization; DTT, dithiothreitol; Fmoc, fluorenylmethoxycarbonyl; MBHA, 4-methylbenzhydrylamine; Boc, tertbutoxycarbonyl; HBTU, N,N,N9,N9-tetramethyl-O-(1H-benzotriazol-1yl)uronium hexafluorophosphate; HOBt, 1-hydroxybenzotriazole; DMF, N,N-dimethylformamide;EDCI,N-(3-dimethylaminopropyl)-N9-ethylcarbodiimide; HOAt, 1-hydroxy-7-azabenzotriazole; DIEA, N,N-diisopropylethylamine; HPLC, high-performance liquid chromatography; TFA, trifluoroacetic acid; MALDI, matrix-assisted laser desorption/ionization; MS,massspectrometry;NMR,nuclearmagneticresonance;TOF,time-offlight;ESI,electrosprayionization;DCC,N,N9-dicyclohexylcarbodiimide; DCU, N,N9-dicyclohexylurea; NMP, N-methylpyrrolidine; Mtt, 4-methyltrityl; DCM, dichloromethane; RP, reverse-phase; HATU, O-(7-azabenzotriazol-1-yl)-N,N,N9,N9-tetramethyluronium hexafluorophosphate; Trt,trityl;DMSO,dimethylsulfoxide;NP,normal-phase;TES,triethylsilane;mP,millipolarizationunits;MW,molecularweight.

ofitsinhibitiontonotonlycaspase-9butalsocaspase-3and caspase-7. Several laboratories, including ours, have reported the designofsmall-moleculeSmacmimeticsoftheAVPIbindingmotifasantagonistsofXIAP[18­21],andmostofthese studieshavefocusedonthedesignofsmall-moleculeSmac mimetics that target the XIAP BIR3 domain. However, becauseboth theBIR2andBIR3domains inXIAPeVectivelysuppressapoptosis,smallmoleculesthatconcurrently targetbothBIRdomains,bymimickingthemodeofbindingofSmacproteintoXIAP,couldbeparticularlyeVective XIAPantagonists.Arecentstudyhasindeedshownthata bivalent,small-moleculeSmacmimetic(compound3inthe originalpublication)antagonizesXIAPwithapotencythat may exceed that of Smac protein in a cell-free functional assay[19].Itwasproposedthattheextremelyhighpotency ofthisbivalentSmacmimeticasanXIAPantagonistcould beattributedtoitsbivalentcharacterandthatitmayinteract simultaneously with both BIR2 and BIR3 domains in XIAP[19],buttheprecisemodeofbindingofthisbivalent SmacmimetictoXIAPhasnotbeendetermined. To elucidate the interaction between bivalent Smac mimeticsandXIAP,andtodeterminewhetherconcurrent targetingoftheBIR2andBIR3domainsisahighlyeVective strategytoantagonizeXIAP,wehavedesignedandsynthesizedabivalentSmac-basedpeptideligand,namedSmac-1, which contains two Ala-Lys-Pro-Phe-NH2 (AKPF-NH2) tetrapeptide binding motifs tethered by a flexible linker (Fig.1A).Inaddition,wedesignedandsynthesizeditsfluorescentlylabeledanalogue,namedSmac-1F(Fig.1B).Using fluorescencepolarization(FP)assaysandanalyticalgelfiltrationexperiments,weinvestigatedtheinteractionofthese bivalent Smac peptide ligands and their monovalent control compounds with diVerent XIAP constructs and their ability to antagonize XIAP in cell-free functional assays. OurstudyclearlydemonstratesthatbivalentSmacpeptide ligandsconcurrentlybindtobothBIR2andBIR3domains inXIAPwithamuchhigheraYnitythandothecorresponding monovalent ligands. Consistent with the binding data, bivalentligandsarealsomuchmorepotentantagonistsof XIAP than are monovalent ligands in cell-free functional assays. Interestingly, bivalent ligands also bind to XIAP BIR3-onlyproteinwithhigheraYnitiesthandothecorresponding monovalent ligands by inducing dimerization of theprotein.Thisstudyprovidesnewinsightsintothemode of action of bivalent Smac ligands targeting XIAP and a solidfoundationforthedesignanddevelopmentofcell-permeable,bivalentSmacmimeticstoconcurrentlytargetboth BIR2andBIR3domainsinXIAPaspowerfulpharmacologicaltoolsandpotentiallyusefultherapeuticagents. Materials and methods Protein expression and purification DiVerentconstructsofhumanXIAPs,includinglinker­ BIR2­BIR3 (residues 120­356), BIR3 (residues 241­356)

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

89

A
O H2N H N O N O H N O NH2

B
O H2N H N O N O H N O NH2

HN

O

HN

O

O

NH

O

NH

O H2N N H N O O N H N H CONH2 O NH2
H2N

O N H N O O N H N H CONH2 O N H HO O O O O OH

C

Peptide Smac-2 Smac-3 Smac-4 Smac-5

Amino acid sequence (CH3)-AKPF-NH2 AKPF-NH2 AKPFK-NH2 AK(Ac)PFK-NH2

Fig.1.(A)ChemicalstructureofSmac-1,adesignedbivalentSmacmimeticpeptide.(B)Smac-1F,afluorescentlytaggedanalogueofSmac-1.(C)MonovalentcontrolSmac-basedpeptides.

and linker­BIR2 (residues 120­240), were cloned into pET28 vector (Novagen) containing an N-terminal 6£ Histag.BIR2­BIR3(residues156­356),withoutthelinker precedingBIR2,wasclonedintoamodifiedHIS­TEVvectorwithanN-terminal8£Histag.Themutatedproteins, BIR2(E219R)­BIR3andBIR2­BIR3(E314S,W323E),were created using QuikChange mutagensis (Stratagene) on a BIR2­BIR3(residues156­356)template.ProteinswereproducedinEscherichia coliBL21(DE3)cellsgrownat37°Cin 2£ YT containing kanamycin to an OD600 of 0.6. Protein expressionwasinducedby0.4mMIPTGat20°Cfor20h (linker­BIR2­BIR3),20°Cfor4h(BIR2­BIR3),37°Cfor 3h(linker­BIR2),or27°Cfor4h(BIR3).Cellswerelysed by sonication in buVer containing 50mM Tris (pH 7.5), 200mMNaCl,50lMZnAc,0.1%bME,andleupectin/aprotinproteaseinhibitors.ProteinswerepurifiedfromthesolublefractionusingNi­NTAresin(Qiagen)followedbygel filtrationonaSuperdex75columnin20mMTris(pH7.5), 200mMNaCl,50lMZnAc,and1mMDTT.Afterpurification,DTTwasaddedtoafinalconcentrationof10mM. Synthesis of peptides General methods Allpeptidesweresynthesizedusingstandardsolidphase peptide chemistry with Fmoc-protected amino acids on

Rink amide MBHA resin or Sieber resin on a 0.1-mmol scale. The Rink amide MBHA resin was purchased from Novabiochem,andtheacid-sensitiveSieberresinwaspurchased from Aldrich. Fmoc- and Boc-protected (Ala and N-methyl-Ala) amino acids were obtained from Anaspec, AdvancedChemtech,andChem-ImpexInternational.The side chain protection groups used were (Fmoc)Lys(Mtt)OH and (Boc)Lys(Fmoc)-OH. HBTU/HOBt activation of Ne-protectedaminoacidswasemployedforcoupling,and 20% piperidine/DMF was used for Fmoc deprotection. EDCI/HOAt/DIEAinDMFwasusedforcouplingoftwo peptides. Crude peptides were purified by semipreparative reverse-phaseornormal-phaseHPLCunderthefollowing conditions:VydacC18column(22£250mm);solventsystemA,0.05%TFAinwater;B,0.05%TFAin90%acetonitrileinwater;gradient,10to80%Bover30min;Spherisorb S5W(20£250mm);solventsystemA,0.5%TFAinisopropanol;B,0.5%TFAinwater;gradient,0%Bover10min, 0to20%over40min;flowrate,10.0ml/min;UVdetector, 225nm.ThepurityofproductswascharacterizedbyanalyticalHPLCandMALDI­MS.HPLCusingtwodiVerentconditions:(a)(I)MerckChromolithPerformanceRP-18ecolumn(100£4.6mm)gradient10to60%Bover9min;flow rate,5.0ml/min;UVdetector,225nm;(II)MerckChromolith Performance RP-18e column (100£4.6 mm) gradient 0to20%Bover9min;flowrate,5.0ml/min;UVdetector,

90

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

225nm; (b) (I) Agilent Zorbax 3.5lm SB-CN column (75£4.6mm) gradient 0 to 60% B over 12min; flow rate, 2.0ml/min;UVdetector,225nm;(II)AgientZorbax3.5lm l SB-CN column (75£4.6mm) gradient 0 to 20% B over 12min; flow rate, 2.0ml/min; UV detector, 225nm. Flash column chromatography was performed with 10 to 40lm silica gel (TM Chemicals). NMR spectra were obtained usingaBruker300-MHzNMR.MALDI­TOF­MS(KratosAxima-CFRinstrument,matrix:a-cyano-4-hydroxycinnamicacid)orESI­MS(FinniganLTQ)wasusedtoverify themolecularmassofallpeptides. Synthesis of Smac-1 and Smac-1F Peptide1wassynthesizedusingtheproceduredescribed inScheme1A.TheRinkamideMBHAresin(0.78mmol/g) wastreatedasanamideresininautomatedpeptidesynthesis with an ABI 433A Peptide Synthesizer using chemical protocolsbasedonFmocchemistry(couplingwithHBTU/ HOBt/DIEA in NMP). On completion of the sequence (Fmoc)AK(Mtt)PF-NH-RinkamideMBHAresin,theMtt protectinggrouponLyswasremovedbytreatmentwith1% TFAinDCM(5ml)toaVordtheresin-boundpeptide.Subsequently,thispeptidewasreactedwithoxepane-2,7-dione, prepared by mixing 0.5M HOOC(CH2)4COOH/DCM (263mg, 1.8mmol, 3.0ml) and 0.6M DCC/DCM (186mg, 0.9mmol,1.5ml)for0.5hatroomtemperature.TheprecipitatedDCUwasfilteredoV,andthesolventwasevaporated

underN2.TheprecipitantwasdissolvedinDMF(4ml)and added to the peptide resin, which was swollen in 1ml of DMF.Theresultingreactionmixturewasshakenatroom temperaturefor12hwhentheninhydrintestwasnegative. ThepeptidewascleavedfromtheresinbyusingTFA(4ml) containing2.5%(v/v)eachoftriethylsilane(0.1ml)anddeionizedwater(0.1ml)for2h.Forisolationoftheproduct,twothirdsofthecleavagereagentmixturewasevaporatedunder N2andthemixturewastrituratedwithice-coldether.The crude peptide 1 was purified by RP­HPLC, tRD18.8min (gradient20­100%Bover35min);MALDI­MS(M+Na)+ 833.1(calcd833.4). The peptide 2 was synthesized by using the procedure describedinScheme1B.TheSieberamideresin(0.45mmol/ g) was treated as an amide resin automated peptide s  ynthesiswithanABI433APeptideSynthesizerusingthe chemical protocols based on Fmoc chemistry (coupling with HBTU/HOBt/DIEAin NMP).On completion ofthe sequence (Fmoc)AK(Mtt)PFK(Boc)-NH-Sieber amide resin, the peptide was cleaved from the resin and the Mtt protectinggrouponLyswasremovedbytreatmentwith1% TFA in DCM (5ml). The crude peptide 2 was purified by RP­HPLC,tRD19.9min(gradient20­100%Bover35min); MALDI­MS(M+Na)+933.5(calcd933.5). The peptide Smac-1 was synthesized by using the proceduredescribedinScheme1C.Toasolutionofpeptide1 (17.7mg,0.0219mmol),EDCI·HCl(10.04mg,0.0524mmol),

A
NH2

a

Fmoc-Ala-Lys(Mtt)-Pro-Phe-NH

b

Rink amide MBHA resin c Fmoc-Ala-Lys-Pro-Phe-NH NH O d

Fmoc-Ala-Lys-Pro-Phe-NH NH2

Fmoc-Ala-Lys-Pro-Phe-NH2 NH O 1 NH2

O

OH

O

OH

B
NH2 Sieber resin

e

C
Fmoc-Ala-Lys(Mtt)-Pro-Phe-Lys(Boc)-NH
1+2 g

H2NOC

NH O NH O O

NHFmoc HN O N H
3

O

N HN O O

f

Fmoc-Ala-Lys-Pro-Phe-Lys(Boc)-NH2 2

O O HN O

NH

N

FmocHN

NH2
h Smac-1

i Smac-1F

Scheme1.SynthesisofSmac-1andfluorescentlabeledanalogueSmac-1F.Reagentsandconditions:(A)(a)(i)HBTU/HOBt/DIEAinNMP,(ii)20%piperidineinNMP,(iii)threecyclesofFmocSPPSwithHBTU/HOBt/DIEAcoupling,(iv)Fmoc­alanine,HBTU/HOBt/DIEAinDMF;(b)1%TFAinDCM, 2min,20times;(c)adipicacid,DCC,DCM,DMF,overnight;(d)95%TFA,0.5%TES,0.5%H2OinDCM,2h.(B)(e)(i)HBTU/HOBt/DIEAinNMP, (ii)20%piperidineinNMP,(iii)fourcyclesofFmocSPPSwithHBTU/HOBt/DIEAcoupling,(iv)Fmoc­alanine,HBTU/HOBt/DIEAinDMF;(f)1% TFAinDCM,2min,20times.(C)(g)(i)EDC,HOAt,DIEA,DCM,12h,(ii)50%TFAinDCM,2h;(h)50%piperidineinDCM,10min;(i)(i)5-Fam, HATU/HOAt/DIEAinDMF,3h,(ii)50%piperidineinDCM,10min.

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

91

andHOAt(7.2mg,0.0524mmol)inDCM(1ml)wasadded DIEA (6.79mg, 0.0526mmol) at 0°C. Subsequently, the peptide2(23.86mg,0.0262mmol)inDCM(0.5ml)solution wasaddeddropwise,andtheresultingsolutionwasstirred atroomtemperaturefor12h.Thesolventwasevaporated andtheresiduewasdissolvedinEtOAc,washedwithH2O andbrine,anddriedoverNa2SO4.Thesolventwasremoved andtheresiduewasdissolvedinDCM(2ml).Totheabove solution, TFA (2ml) was added at 0°C, and the resulting solutionwasstirredatroomtemperaturefor2h.Afterthe solvent was removed, 35mg of the crude peptide 3 was obtained.MALDI­MS(M+Na)+1626.0(calcd1625.8).The crudepeptide3(10mg)wasdissolvedinDCM(3ml).Tothe abovesolution,piperidine(1.5ml)wasadded,andtheresultingsolutionwasstirredatroomtemperaturefor10min.The crudeproductSmac-1waspurifiedbyRP­HPLCtogivethe pureproduct(27mg,30%),tRD16.8min(gradient10­100% Bover35min);MALDI­MS(M+H)+1159.9(calcd1159.7); tRD4.26min(conditiona(I),purity98%). The peptide Smac-1F was synthesized using the procedure described in Scheme 1C. To a solution of 5-Fam (41.17mg, 0.110mmol), HATU (41.6mg, 0.110mmol), and HOAt (14.9mg, 0.110mmol) in DMF (1.0ml) was added DIEA(42.5mg,0.329mmol)at0°C.Subsequently,thepeptide 3 (35mg, 0.0219mmol) in DMF (1.0ml) solution was addeddropwisetothissolution,andtheresultingsolution was stirred at room temperature for 3h. After the solvent was removed, the residue was dissolved in DCM (3ml), piperidine (1.5ml) was added, and the resulting solution wasstirredatroomtemperaturefor10min.Thecrudepeptide Smac-1F was purified by RP­HPLC to give the pure product (27mg, 30%), tRD17.9min (gradient 10­100% B over35min);MALDI­MS(M+Na)+1539.7(calcd1539.8); tRD4.50min(conditiona(I),purity96%). Synthesis of Smac-2 TheFmoc-Phe-2-ClTrtresinwastreatedasapreloaded resinautomatedpeptidesynthesiswithanABI433APeptide Synthesizer using the chemical protocols based on Fmoc chemistry(couplingwithHBTU/HOBt/DIEAinNMP).On completion of the sequence (N-methyl)AK(Boc)PF-2-ClTrtresin,theside-chain-protectedpeptidewascleavedfrom theresinandtheBocgroupwasremovedusingthemethod describedabove.ThecrudepeptidewaspurifiedbyRP­HPLC, tRD11.3min(gradient10­80%Bover35min);MALDI­MS (M+H)+ 475.3 (calcd 475.3); tRD3.88min (condition a (II), purity99%);tRD5.42min(conditionb(II),purity98%). 1H NMR (400MHz, D2O): 8.07 (NH, d, JD7.2Hz), 7.25­7.13 (5H,m),4.47(1H,dd,JD5.6,8.4Hz),4.36(1H,m),4.23(1H, dd,JD6.0,8.4Hz),3.81(1H,q,JD7.2Hz),3.66(1H,m),3.48 (1H,m),2.95(2H,d,JD7.6Hz),2.84(2H,t,JD7.6Hz),2.54 (3H, s), 2.08 (1H, m), 1.85 (2H, m), 1.71­1.53 (5H, m), 1.36 (3H,d,JD7.2Hz),1.38­1.30(2H,m)ppm. Synthesis of Fmoc-Ne-acetyl-l-lysine-OH Fmoc-Ne-Boc-l-lysine-OH (1.03g, 2.19mmol) was dissolved in 50% TFA/DCM (10ml), stirred at 23°C for

20min,andthenconcentratedinvacuo.Thecruderesidue wasdissolvedinDCM(10ml)andtreatedwithpyridine(9 eq). The reaction mixture was stirred vigorously, and aceticanhydride(17eq)wasaddedinsevenportionsover2h. The reaction was quenched by adding 0.05 N HCl (10ml) and stirring for an additional 10min. The organic portion wasseparatedandwashedwith0.05NHCl(2£10ml)and H2O(10ml).Thecombinedaqueouswasheswereextracted with DCM (2£10ml), and the combined organic extracts were dried (MgSO4), filtered, and concentrated in vacuo. ThecruderesiduewasdissolvedinEtOAc(5ml)andpurified by flash column chromatography (10% MeOH/89% EtOAc/1%AcOH).Thepeakfractionswerecombined,concentrated,dissolvedinMeOH(6ml),andprecipitatedwith excessH2O.TheprecipitatewasfilteredanddriedundervacuumtoyieldthefinalproductasanoV-whitesolid(0.632g, 1.54mmol, 70%). Rf 0.2 (10% MeOH/89% EtOAc/1% AcOH); 1HNMR(DMSO,300MHz)d7.89(d,JD7.5Hz, 2H),7.72(d,JD7.3Hz,2H),7.42(t,JD7.1Hz,2H),7.32(t, JD6.9Hz, 2H), 4.29­4.24 (m, 3H), 3.89 (dt, JD4.5, 8.6Hz, 1H),3.00(app.q,JD5.6Hz,2H),1.70­1.50(m,2H),1.40­ 1.25(m,4H); 13CNMR(DMSO,75.5MHz)d175.1,169.9, 157.0,144.7,141.6,128.5,127.9,126.2,121.0,66.4,54.8,47.5, 39.2,31.4,29.6,24.0,23.5. Synthesis of Smac-3, Smac-4, and Smac-5 ThepeptidesSmac-3,Smac-4,andSmac-5weresynthesized manually using standard Fmoc solid-phase peptide synthesis techniques. Rink amide resin (1.2mmol/g) was deprotectedwith20%piperidine/DMFfor30minandthen filteredandwashedwithDMF(3ml),MeOH(2£3ml),and DMF(2£3ml).Thefirst Fmoc-protected aminoacid(1.5 eq)wasloadedusingHATU(1.5eq),HOAT(1.5eq),and DIEA (2 eq); dissolved in DMF (3ml); and shaken for 3 to4h.Theresinwasfiltered,washedwithDMF(2£3ml), andtreatedwithaceticanhydride(2eq)andpyridine(2eq) in DMF (3ml) for 35min. The remaining Fmoc-protected amino acids with the appropriate side-chain-protecting groupswerecoupledasabove.Boc-l-alanine-OHwasused asthelastaminoacid.Thefinal,resin-bound,Boc-protected peptides were washed with 1% TFA/DCM (3£2ml) and cleavedfromtheresinandsimultaneouslydeprotectedwith 95%TFA/2.5%TES/2.5%DCM(4£2mlfor20min).The cleavagesolutionwasconcentratedinvacuoandtriturated with excess cold diethyl ether. The crude precipitate was purifiedbyNP­HPLC,andthestructureofthefinalproductwasverifiedbyESI­MS.ESI­MSAKPF-NH2m/zcalcd for[M+H]+461.29,found461.36;AKPFK-NH2m/zcalcd for [M+H]+ 589.38, found 589.45; AK(Ac)PFK-NH2 m/z calcdfor[M+H]+631.39,found631.45. FP assay FPexperimentswereperformedin96-well,blackroundbottom plates (Microfluor 2, Fisher Scientific) using the Ultraplatereader(Tecan).Toeachwell,1nMoffluorescein-labeledprobe(Smac-1F)andconcentrationsranging

92

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

from0to20lMofdiVerentconstructsofXIAP(BIR3(residues 241­356), linker­BIR2 (residues 120­240), linker­ BIR2­BIR3 (residues 241­356), BIR2­BIR3 (residues 156­356), and the mutated proteins BIR2(E219R)­BIR3 andBIR2­BIR3(E314S,W323E))wereaddedtoafinalvolumeof125llintheassaybuVer(100mMpotassiumphosphate(pH7.5),100lg/mlbovinec-globulin,0.02%sodium azide,Invitrogen,LifeTechnologies).Theplatewasmixed on a shaker for 15min and incubated at room temperature for 3h to reach equilibrium. The polarization values inmillipolarization(mP)unitsweremeasuredatanexcitationwavelengthof485nmandanemissionwavelengthof 530nm. For assay stability testing, a plate was measured atdiVerenttimesovera24-hperiod.Anequilibriumbinding isotherm was constructed by plotting the FP reading asafunctionoftheXIAPconcentrationatafixedconcentrationoftheprobe.Allexperimentaldatawereanalyzed using Prism 3.0 software (GraphPad Software), and the inhibition constants were determined by nonlinear curve fittingastheconcentrationoftheXIAPatwhich50%of theligandisbound. Inthecompetitivebindingexperiments,thetestedSmac peptide mimetic was incubated with 3nM XIAP (residues 120­356) and 1nM Smac-1F in the assay buVer (100mM potassiumphosphate(pH7.5),100lg/mlbovinegammaglobulin, 0.02% sodium azide) in 96-well, black, round-bottom plates.Foreachassay,theboundpeptidecontrolcontaining XIAP and Smac-1F peptide (equivalent to 0% inhibition) andfreepeptidecontrolcontainingonlyfreeSmac-1Fpeptide(equivalentto100%inhibition)wereincludedoneach assayplate.Thepolarizationvaluesweremeasuredafter3 hincubation,whenthebindingreachedequilibrium,using theUltraplatereader(Tecan).Theinhibitorconcentration atwhich50%ofboundpeptideisdisplaced(IC50)wasdeterminedfromtheplotusingnonlinearleastsquaresanalysis, andcurvefittingwasperformedusingGraphPadPrismsoftware.TheKivalueswerecalculatedusinganequationdevelopedforFPassays[22]. Analytical gel filtration AnalyticalgelfiltrationexperimentswithBIR3(residues 241­356) and BIR2­BIR3 (residues 156­356) were performedonaSuperdex75column(GEHealthcare)attached to an AKTA Purifier-10 system in 20mM Tris­HCl (pH 7.5), 200mM NaCl, 50lM zinc acetate, and 1mM DTT. Recombinantproteinwasrunonthecolumnataconcentrationof1mg/mlaloneorafterincubationwitha1:1molar ratioofSmacpeptideligands.Molecularweightstandards obtainedfromAmershamPharmaciawereusedtocalibrate thecolumn. Cell-free functional caspase assay MDA-MB-231celllysateswerepreparedbysolubilizing cells in ice-cold buVer (50mM KCl, 5mM EGTA, 2mM MgCl2,1mMDTT,0.2%Chaps,and50mMHepes(pH7.5)

containing cocktail protease inhibitors), incubating on ice for10minandthenfreezinginliquidnitrogen. Caspase-9andcaspase-3/caspase-7wereactivatedbyadding cytochrome c and dATP and incubating at 30°C in a waterbathfor60min.TheadditionofrecombinantXIAP linker­BIR2­BIR3protein(50nM)inthecelllysatescompletely suppressed the activity of caspase-9 and caspase-3/ caspase-7.DiVerentconcentrationsofatestedSmacmimetic (from1nMto100lM)wereaddedtodeterminetherestoration of the activity of these caspases. For determination ofcaspaseactivity,25lMofeithercaspase-9substrate(ZLEHD-AFC) or caspase-3/caspase-7 substrate (Z-DEVDAFC)(BioVision)wasadded.Fluorescencedetectionofsubstratecleavagebycaspase-9orcaspase-3/caspase-7fortheir specificsubstratewascarriedoutonanUltraplatereader usinganexcitationwavelengthof400nmandanemission wavelengthof505nm.Thereactionwasmonitoredfor1to 2h. Results Design of a bivalent peptide-based Smac mimetic and its fluorescently labeled probe SmacproteinbindstoboththeBIR2andBIR3domains throughatetrapeptideAVPIbindingmotif[14,16].Apreviousstudyshowedthatreplacementofthesecondresidue (valine)intheSmacAVPIpeptidewithlysinedoesnothave a detrimental eVect on binding to XIAP BIR3 and that replacementofthefourthresidue(isoleucine)byphenylalanineimprovesthebindingaYnitytoXIAPBIR3[23].In addition, the crystal structure of XIAP BIR3 complexed withSmacshowsthatthesecondresidueisexposedtosolvent[16].Accordingly,inourdesign,wereplacedthesecond residue(valine)withlysineandreplacedthefourthresidue with phenylalanine, and we use the AKPF-NH2 tetrapeptideasthemonovalenttemplate. Theexperimentallydeterminedthree-dimensionalstructure of XIAP containing both BIR2 and BIR3 domains hasnotbeenreported.Ouranalysisshowedthatthelinker regionbetweenBIR2andBIR3,containingapproximately 25residues,doesnothaveawell-definedsecondarystructureandshouldbequiteflexible.Thus,wedesignedandsynthesizedabivalentSmac-basedpeptide,Smac-1(Fig.1A), which contains two tetrapeptide binding motifs (AKPFNH2) linked by a flexible linker, adipic acid, through the side chains of the two lysine residues. We reasoned that suchalinkerwouldprovidesuY ientlengthandflexibility c for the two tetrapeptide binding units in Smac-1 to bind concurrentlytobothBIR2andBIR3domainsinthesame XIAPmolecule. Using Smac-1 as the basic bivalent Smac mimetic template,wedesignedafluorescein-conjugatedanalogue,Smac1F,inwhichthefluorescenceprobeistetheredtotheCterminus of one of the AKPF-NH2 binding units. To ensure thatthefluorescenceprobedoesnotinterferewiththebindingoftheAKPF-NH2bindingunit,weaddedalysineafter

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

93

the phenylalanine residue and conjugated the fluorescence probe to the amino group on the side chain of the lysine (Fig. 1B). We also synthesized several related monovalent peptides--N-methylated AKPF-NH2 (Smac-2), AKPFNH2 (Smac-3), AKPFK-NH2 (Smac-4), and A-K(acetylated)-PFK-NH2 (Smac-5)--as the control compounds in ourstudy(Fig.1C). Evaluation of Smac-1F binding aYnities against diVerent XIAP constructs WeemployedanFPbindingassaytodeterminethebinding aYnities of Smac-1F to several diVerent constructs of XIAP.TheseXIAPconstructsincludedBIR3only(residues 241­356,hereaftercalledBIR3),linker­BIR2(residues120­ 240,hereaftercalledL­BIR2),linker­BIR2­BIR3(residues 120­356,hereaftercalledL­BIR2­BIR3),andBIR2­BIR3 without the linker preceding the BIR2 domain (residues 156­356, hereafter called BIR2­BIR3). The linker precedingtheBIR2domain(residues138­149)inXIAPisknown tobecriticalforbindingtoandinhibitionofcaspase-3and caspase-7butmightnotbeinvolvedindirectbindingwith Smacprotein(Scheme2). The dissociation constant (Kd) of Smac-1F to each XIAPconstructwasdeterminedusingafixedconcentration of Smac-1F with diVerent concentrations of the protein. Because the polarization value is derived from the ratio of bound probe versus free probe, we used a low concentrationoftheprobethatwouldyieldareasonablefluorescentsignaland,therefore,astablepolarizationvaluewith goodsignal-to-noisecharacteristics.Fig.2illustratesanonlinear least squares fit to a single-site binding model for a saturationexperimentinwhichconcentrationsupto2lM forL­BIR2­BIR3,upto5lMforBIR3,andupto20lM for L­BIR2 were used with constant probe concentration of1nM.ThesetitrationexperimentsshowedthattheSmac1Fhasdissociationconstants(Kd)of2.3,8.3,and2581nM toL­BIR2­BIR3,BIR3,andL­BIR2proteins,respectively. TotestwhetherthelinkerprecedingBIR2isinvolvedinthe binding,wealsomadeXIAPcontainingBIR2­BIR3(residues156­356)withoutthelinkeranddeterminedthatthis proteinbindstoSmac-1FwithaKdvalueidenticaltothatof L­BIR2­BIR3(KdD2.0nM),indicatingthatthelinkerprecedingBIR2isnotinvolvedinthebinding.Thesebinding data showed that Smac-1F binds to XIAP L­BIR2­BIR3 andBIR3proteinswithveryhighaYnitiesbutbindstoL­ BIR2proteinwithamuchweakeraYnity.

Kd ± SD nM BIR3 BIR2
300

8.3 ± 1.7 2.581 ± 1.368

L-BIR2-BIR3 2.3 ± 0.5

200

mP
100 0

-2.5

0.0

2.5

5.0

[Proteins] (log [nM])
Fig.2.SaturationcurvesofthreediVerentconstructsofXIAP--BIR3(residues241­356),L­BIR2(residues120­240),andL­BIR2­BIR3(residues 120­356)--tobivalentSmacmimeticpeptideSmac-1F.

Smac-1F binds to BIR2­BIR3 and BIR3 with diVerent binding modes OurbindingdatashowingthatSmac-1FbindstoBIR3 and BIR2­BIR3 (L­BIR2­BIR3) proteins with very similaraYnitiessuggestthepossibilitythatSmac-1Fmaybind to these two proteins with similar binding modes. To test thispossibility,weperformedanalyticalgelfiltrationexperiments using diVerent XIAP constructs. The results are showninFig.3. IntheabsenceofSmac-1F,itisevident,judgingbytheir apparentmolecularweights(MWs),thatbothBIR2­BIR3 and BIR3 proteins exist as monomers. In the presence of Smac-1F, the apparent MW of BIR2­BIR3 protein is 20.6kDa,slightlylessthanthatofthemonomer(23.8kDa) without Smac-1F, indicating a more compact monomeric form of BIR2­BIR3, consistent with the tight binding of Smac-1FtoBIR2­BIR3(Fig.3B).Incontrast,theapparent MWofBIR3inthepresenceofSmac-1Fis29.1kDa,essentially twice the MW of the monomeric BIR3 (17.9kDa), suggesting the formation of BIR3 dimer in the presence ofSmac-1F(Fig.3A).Hence,theseanalyticalgelfiltration dataprovideclearevidencethatSmac-1Fformsa1:1complexwithBIR2­BIR3proteinbutformsa1:2complexwith BIR3-onlyprotein.Thus,thebindingmodeofSmac-1Fto BIR3isdiVerentfromthatofSmac-1FtoBIR2­BIR3.EssentiallyidenticalresultswereobtainedforunlabeledSmac-1 (Figs. 3A and B). In sharp contrast, monovalent Smac-2 doesnotcausedimerizationtoeitherXIAPBIR2­BIR3or XIAPBIR3protein(Figs.3AandB). Both BIR2 and BIR3 domains are directly involved in the binding of Smac-1F to XIAP BIR2­BIR3 protein Although the binding experiments showed that Smac1F binds to BIR2­BIR3 with a high aYnity, and the gel filtration studies indicate that Smac-1F does not cause

120

156

240241 L-BIR2-BIR3 BIR2-BIR3

356

L-BIR2 BIR3

Scheme2.

94

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

A

BIR3 only (Apparent MW = 17.9 kDa) BIR3 + Smac-1F (Apparent MW = 29.1 kDa) BIR3 + Smac-1 (Apparent MW = 29.9 kDa) BIR3 + Smac-2 (Apparent MW = 17.5 kDa)
300

Kd ± SD nM BIR2-BIR3 BIR2-(E219R)-BIR3 2.0 ± 0.07 91.36 ± 56.0

BIR2-BIR3(E314S;W323E) 72.72 ± 10.02

100 75 50 25 0 50
0 200

A280

70

mP
100 -2.5

0.0

2.5

5.0

Elution Volume [ml]

[Proteins] (log [nM])
Fig.4.Saturationcurvesofwild-typeXIAPBIR2­BIR3protein(residues 156­356) and two mutated proteins, BIR2(E219R)­BIR3 and BIR2­ BIR3(E314S,W323E),tobivalentSmacmimeticpeptideSmac-1F.

B

BIR2-BIR3 (Apparent MW = 23.8 kDa) BIR2-BIR3 + Smac-1F (Apparent MW = 20.6 kDa) BIR2-BIR3 + Smac-1 (Apparent MW = 22.2 kDa) BIR2-BIR3 + Smac-2 (Apparent MW = 22.0 kDa)
100 75 50 25 0 50

70

Elution Volume [ml]
Fig.3.AnalyticalgelfiltrationofBIR3(A)andBir2­Bir3(B)proteinalone orinthepresenceofbivalentSmacmimeticpeptides(Smac-1andSmac1F) and monovalent peptide (Smac-2). The apparent molecular weights (MWs)areshowninparentheses.

d  imerizationoftheBIR2­BIR3protein,theseexperiments donotprovidedirectevidencethatSmac-1FdirectlyinteractswiththeBIR2orBIR3domainswhenpresentinasingleXIAPmolecule.Todirectlytesttheinvolvementofthese BIRdomainsintheinteractionwithSmac-1F,wemadetwo mutated Bir2­Bir3 proteins selectively knocking out the bindingofeachdomain. BasedontheNMRstructureoftheBIR2domain,theglutamicacidresidueE219islocatedintheBIR2bindinggo ve o andmayinteractwiththepositivelychargedaminogroupin theSmacAVPIbindingmotif.Mutationofthisnegatively charged residue to a positively charged arginine should disrupttheinteractionbetweenthenegativelychargedcarboxylic acid in the side chain of E219 with the positively chargedprimaryaminegroupinthefreealanineresiduein the AKPF binding unit. Accordingly, we mutated Glu219 to arginine (E219R mutation) in the BIR2­BIR3 protein. IfBIR2isdirectlyinvolvedinthebindingtoSmac-1F,this mutationwillreducethebindingaYnityoftheBIR2­BIR3 protein.SaturationexperimentsshowedthatSmac-1Fbinds tothismutatedproteinwithaKdvalueof92nM(Fig.4),a

46-fold decrease in binding aYnity compared with that to wild-typeXIAPBIR2­BIR3protein.Thus,thismutational analysisprovidesstrongevidencethattheBIR2domainis directlyinvolvedinthebindingofSmac-1FtoXIAPcontainingbothBIR2andBIR3domains. AnalysisofXIAPBIR3crystalstructureincomplexwith Smacproteinshowedthatglutamate314(E314)andtryptophan323(W323)inXIAPinteractwiththeSmacAVPI bindingmotif.Therefore,wemutatedE314toserine(E314S) and W323 to glutamate (W323E) in XIAP BIR2­BIR3 protein.OursaturationexperimentsshowedthatSmac-1F bindstothisdoublymutatedXIAPBIR2­BIR3(E314Sand W323E)proteinwithaKdvalueof73nM(Fig.4),indicating thatBIR3isalsodirectlyinvolvedinthebindingofXIAP BIR2­BIR3proteintoSmac-1F. Collectively, our data clearly show that Smac-1F interactsconcurrentlywithboththeBIR2andBIR3domainsin XIAPandformsa1:1complexwithXIAPcontainingboth BIR2andBIR3domains. Development and validation of a competitive FP-based assay using Smac-1F as the probe In the saturation experiment, Smac-1F binds to XIAP containingbothBIR2andBIR3domainswithaKdvalueof 2.3§0.5nM(Fig.2)andisahigh-aYnitybivalentpeptidebased Smac mimic. Using this high-aYnity fluorescently tagged bivalent peptide and XIAP containing both BIR2 andBIR3domains,weestablishedandvalidatedacompetitiveFP-basedassaytoinvestigatethebindingofotherSmac mimetics to the XIAP containing both BIR2 and BIR3 domains. We first further assessed the true Kd value of Smac-1F to XIAP L­BIR2­BIR3 using diVerent concentrations of Smac-1F. In principle, when the probe concentration is above the true Kd value, a higher probe concentration should result in a higher apparent Kd value. Using three d  iVerentconcentrationsoftheprobe--5,1,and0.5nM--we

A280

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

95

measured15.7,3.1,and2.1nM,respectively,astheapparent Kdvalues(Fig.5A).Thesedataindicatethattheapparent Kdvalueobtainedusing0.5nMofthetracerapproachesthe trueKdvaluefortheSmac-1F/XIAPL­BIR2­BIR3interaction. ThestabilityoftheXIAPFPassaywasevaluatedwith diVerentincubationtimesupto24hatroomtemperature. Ourresultsshowedthattheassayisstable;boththeKdvaluesandthesignalsobtainedremainedunchangedfor24h (Fig.5B). WethenevaluatedacompetitiveFPassayusingbivalent Smac-1FasthetracerforthedeterminationofbindingaYnitiesofunlabeledSmacmimeticstoXIAPcontainingboth BIR2andBIR3domains.Inthiscompetitiveassay,afixed concentrationofSmac-1F(1nM)andXIAPL­BIR2­BIR3 protein (3nM) was employed. Unlabeled bivalent Smac-1 wasusedtodetermineitsabilitytocompeteoVthebinding ofSmac-1FtoXIAP,andinadditiontobivalentSmac-1,we alsoevaluatedmonovalentSmacAVPIpeptideandSmac2 in this assay (Fig. 6). Smac-1 was found to compete oV Smac-1Finadose-dependentmannerandhasanIC50value of3.93nMwithacalculatedKivalueof1.64nM.Incomparison,monovalentAVPIpeptideandSmac-2haveIC50values

Inhibitor[IC50 ± SD [nM] (Ki ± SD [nM])] AVPI [10,396 ± 2,697 (4,329 ± 1,123)] Smac-1 [3.93 ± 1.1 (1.64 ± 0.5)] Smac-2 [2,499 ± 399 (1,040 ± 166)] Smac-3 [1,585 ± 569 (659 ± 237)] Smac-4 [2,538 ± 653 (1,057 ± 272)] Smac-5 [4,774 ± 1,282 (1,808 ± 223)] Compound 3 (Ref. [19]) [0.75 ± 0.11 (0.31 ± 0.05)]
100

% Inhibition

50

0 -2.5 0.0 2.5 5.0

[Inhibitor] (log [nM]) Fig. 6. Binding aYnities of bivalent and monovalent Smac mimetics to XIAP(residues120­356)containingBIR2andBIR3domainsdetermined inacompetitiveFP-basedassay.

A
300

0.5 nM Smac-1F Kd = 2.1 nM 1.0 nM Smac-1F Kd = 3.1 nM 5 nM Smac-1F Kd = 15.7 nM

200

100

0 -3 -2 -1 0 1 2 3

[Protein] (log [nM])

B
300

1h 3h 6h 24 h

Kd = 1.9 nM Kd = 2.1 nM Kd = 2.0 nM Kd = 2.5 nM

200

100

0 -3.5 -1.0 1.5

[Protein] (log [nM])

Fig.5.(A)BindingisothermsoffluorescentbivalentSmacpeptideSmac-1F toL­BIR2­BIR3usingdiVerentconcentrationsofprobe.(B)Stabilityof XIAPFP-basedassay.

of10,396and2499nM,respectivelyand,thus,aremorethan 1000and636timeslesspotentthanthebivalentSmac-1. Wesynthesizedthreeadditionalmonovalentcontrolpeptides--Smac-3, Smac-4, and Smac-5--and evaluated their bindingaYnitiestoL­BIR2­BIR3protein(Fig.6).Smac-3 has the same structure as Smac-2 but lacks the N-methyl group,Smac-4isAKPKK,andSmac-5isSmac-4withan acetylated lysine side chain. Our binding studies showed that Smac-3 binds to XIAP L­BIR2­BIR3 with an IC50 valueof1.58§0.56lM,similartotheIC50valueforSmac-2 (2.50§0.40lM),indicatingthattheN-methylgrouphada minimaleVectonthebindingofSmac-2toXIAP.Smac-4, withanextralysineresiduerelativetoSmac-3,hasanIC50 valueof2.54§0.65lM,similartothevaluesforbothSmac2andSmac-3.Thus,thesedataindicatethattheextralysine residueinSmac-4makesnosignificantcontributiontobinding.Smac-5,synthesizedtotesttheeVectofacetylationon thesidechainofthelysineresidueinthe2position,hasan IC50valueof4.77§1.28lMand,thus,is2timeslesspotent thanSmac-4.Thesebindingdata,measuredinacompetitive binding assay, showed that the higher binding aYnity for Smac-1toL­BIR2­BIR3thanforSmac-2toL­BIR2­BIR3 isnotduetotheextralysineresidueononebindingunitor totheacetylationofthelysinesidechain. OnebivalentSmacmimeticwasreportedpreviously[19]. Interestingly, this bivalent Smac mimetic (compound 3 in theoriginalpublication)wasshowntobindtoXIAPBIR3 withanIC50valueof0.12lM,onlytwiceaspotentasthe AVPFpeptideunderthesameassayconditions.However, usingapolyacrylamidegelelectrophoresisassay,itwasdemonstratedthatitspotencytorecombinantfull-lengthhuman XIAPmayexceedthatofSmacproteinandcouldbemuch

mP

mP

96

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

more potent than the AVPF peptide [19]. Thus, we evaluated the binding aYnity of this bivalent Smac mimetic to XIAPL­BIR2­BIR3proteinusingSmac-1Fasthetracerin theFP-basedcompetitivebindingassay.ThisbivalentSmac mimetic was determined to have an IC50 value of 0.75nM toL­BIR2­BIR3protein,withanestimatedKivalueofless than 1nM (Fig. 6). Hence, our binding data showed that thisbivalentSmacmimeticindeedbindstoXIAPcontainingbothBIR2andBIR3domainswithaveryhighaYnity andisinfactmorethan10,000timesmorepotentthanthe AVPIpeptide. Bivalent Smac-based peptide ligand Smac-1 is an extremely potent antagonist of XIAP in cell-free caspase functional assays XIAPbindstocaspase-9throughitsBIR3domainand to caspase-3 and caspase-7 through its BIR2 domain and inhibitstheactivityoftheseenzymes.MatureSmacprotein forms a homodimer and eVectively antagonizes XIAP by bindingtoboththeBIR2andBIR3domainsofXIAPand promotingtheactivityofcaspase-9andcaspase-3/caspase7. Because bivalent Smac mimetics are designed to mimic thebindingmodeofSmacproteintoXIAP,wepredictthat such ligands will function as highly potent antagonists of XIAPbybindingtoboththeBIR2andBIR3domainsand willeVectivelypromotecaspaseactivity. Totestthisprediction,wedevelopedfluorescence-based, cell-freefunctionalcaspaseassaysandevaluatedourSmacbasedpeptideligandsfortheirabilitytoantagonizeXIAP onafunctionallevel.Intheseassays,caspase-9andcaspase3/caspase-7 were activated in cell extracts by the addition of dATP and cytochrome c and were inhibited by the addition of recombinant XIAP L­BIR2­BIR3 protein. ZLEHD-AFCwasusedasacaspase-9-specificsubstrate,and Z-DEVD-AFC was used as a caspase-3/caspase-7-specific

substrate. The activity of caspase-9 or caspase-3/caspase-7 was determined by fluorescence intensity of their specific substratecleavage. As can be seen in Fig. 7, recombinant XIAP L­BIR2­ BIR3proteininhibitstheactivityofcaspase-9andcaspase3/caspase-7 in a dose-dependent manner and completely abolishestheactivityoftheseenzymesat50nM. We then tested the ability of Smac-1 and Smac-2 to antagonize L­BIR2­BIR3 protein in these functional assays. Both bivalent Smac-1 and monovalent Smac-2 restore the activities of caspase-9 and caspase-3/caspase7,butSmac-1ismuchmorepotentthanSmac-2inthese functionalassays,consistentwiththeirbindingaYnitiesto L­BIR2­BIR3 (Fig. 8). For example, at a concentration of300nM,Smac-1restoresmorethan50%oftheactivity of these caspases, whereas Smac-2 at concentrations as highas3000nMhaslesseVectinrestorationoftheactivityofthesecaspases.Thesefunctionaldataprovideclear evidencethatbivalentSmac-1functionsasapotentantagonist of XIAP protein, promotes the activity of caspase9andcaspase-3/caspase-7,andismuchmorepotentthan monovalentSmac-2. Discussion Inthisstudy,weemployedcomplementarybiochemical andfunctionalassaystoinvestigatewhetherbivalentSmacbased peptide ligands can function as much more potent antagonists of XIAP than the corresponding monovalent Smacmimetics.Wealsodeterminedthemodeofbindingof bivalentSmacligandstodiVerentXIAPconstructs. Consistent with our design, our data showed that the bivalent ligand, Smac-1, and its fluorescently labeled analogue, Smac-1F, bind to XIAP containing both BIR2 and BIR3domainswithaKd(Ki)valueofapproximately2nM. Smac-1FbindstotheXIAPconstructcontainingonlythe BIR2domain1000timeslesspotentthanitsbindingaYnity to the XIAP protein construct containing both BIR2 and BIR3domains.Interestingly,Smac-1FalsobindstoXIAP BIR3 protein with a Kd value of 8.3nM and, thus, is only slightlylesspotentthaninitsbindingtoXIAPcontaining both BIR2 and BIR3 domains. Gel filtration experiments, however,provideevidencethatthebivalentligandsSmac-1 andSmac-1FinducecleardimerizationofXIAPBIR3proteinbutdonotcausedimerizationofXIAPcontainingboth BIR2 and BIR3 domains. These data indicate that Smac1 and Smac-1F interact with XIAP containing only the BIR3domainandXIAPcontainingbothBIR2andBIR3 domainswithtwodiVerentbindingmodes.Usingamutated XIAPinwhichacriticalglutamicacid(E219)intheBIR2 domainismutatedtoarginine(E219Rmutant),weshowed thattheBIR2domainisdirectlyinvolvedintheinteraction of Smac-1F with XIAP containing both BIR2 and BIR3 domains.Similarly,usingamutatedXIAPinwhichglutamate314(E314)andtryptophan323(W323)weremutated, wealsoshowedthattheBIR3domainisdirectlyinvolved in the interaction of Smac-1F with XIAP containing both

Max activation (dATP + cyt-c) No activation + L-BIR2-BIR3 (10 nM) + L-BIR2-BIR3 (25 nM) + L-BIR2-BIR3 (50 nM) + L-BIR2-BIR3 (100 nM)
RFU (Caspase-3 Activity)
30000 25000 20000 15000 10000 5000 0 0 10 20 30 40 50 60

Time (min)
Fig.7.XIAPL­BIR2­BIR3(residues120­356)abolishescaspasesactivity inadose-dependentmanner.Max,maximum;cyt-c,cytochromec.RFU, relativefluorescenceunits.

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98

97

A

RFU (Caspase-9 Activity)

15000

10000

RFU (Caspase-9 Activity)

Max activation (dATP + cyt-c) + L-BIR2-BIR3 (50 nM) + L-BIR2-BIR3 + Smac-1 (50 nM) + L-BIR2-BIR3 + Smac-1 (100 nM) + L-BIR2-BIR3 + Smac-1 (300 nM) + L-BIR2-BIR3 + Smac-1 (1,000 nM) + L-BIR2-BIR3 + Smac-1 (10,000 nM)

Max activation (dATP + cyt-c) + L-BIR2-BIR3 (50 nM) + L-BIR2-BIR3 + Smac-2 (1,000 nM) + L-BIR2-BIR3 + Smac-2 (3,000 nM) + L-BIR2-BIR3 + Smac-2 (10,000 nM) + L-BIR2-BIR3 + Smac-2 (100,000 nM)
20000

10000

5000

0

0
0 10 20 30 40 50

0

10

20

30

40

50

Time (min)

Time (min)

B

Max activation (dATP + cyt-c) + L-BIR2-BIR3 (50 nM) + L-BIR2-BIR3 + Smac-1 (50 nM) + L-BIR2-BIR3 + Smac-1 (100 nM) + L-BIR2-BIR3 + Smac-1 (300 nM) + L-BIR2-BIR3 + Smac-1 (1,000 nM) + L-BIR2-BIR3 + Smac-1 (10,000 nM)
30000

Max activation (dATP + cyt-c) + L-BIR2-BIR3 (50 nM) + L-BIR2-BIR3 + Smac-2 (1,000 nM) + L-BIR2-BIR3 + Smac-2 (3,000 nM) + L-BIR2-BIR3 + Smac-2 (10,000 nM) + L-BIR2-BIR3 + Smac-2 (100,000 nM)
RFU (Caspase-3 Activity)
30000

RFU (Caspase-3 Activity)

20000

20000

10000

10000

0

0

10

20

30

40

0

0

10

20

30

40

Time (min)

Time (min)

Fig.8.KineticanalysisforthereliefofL­BIR2­BIR3(residues120­356)mediatedcaspase-9(A)andcaspase-3(B)inhibitionbybivalentpeptideSmac-1 andmonovalentpeptideSmac-2.Max,maximum;cyt-c,cytochromec.RFU,relativefluorescenceunits.

BIR2andBIR3domains.Ofnote,althoughXIAPcontains twobindingdomains,ourdesignedbivalentSmacmi etics m concurrentlybindtowild-typeXIAPcontainingbothBIR2 andBIR3domainswithasinglemodebutnottwobinding modes.Takentogether,ourdatashowthatbivalentSmac1F and Smac-1 concurrently interact with both the BIR2 and BIR3 domains in XIAP containing both domains, therebymimickingthemodeofactionofthematuredimeric Smacprotein. ToevaluatewhetherthehigherbindingaYnitiesforbivalent Smac-based peptide ligands to XIAP would translate to more potent functional antagonism against XIAP, we employed cell-free functional assays and evaluated Smacbasedpeptideligandsinthefunctionalassays.Ourfunctional studiesshowedthatXIAP(L­BIR2­BIR3)containingboth BIR2andBIR3domainsandthelinkerprecedingtheBIR2 potently and eVectively inhibits the activity of caspase-9 andcaspase-3/caspase-7.Consistentwiththebindingdata, bivalent Smac-1 is a highly potent antagonist of XIAP in promotingtheactivityofcaspase-9aswellascaspase-3and

caspase-7inthesecell-freefunctionalassays.Indirectcomparison,bivalentSmac-1isindeedmuchmorepotentthan thecorrespondingmonovalentSmacligandSmac-2. UsingthefluorescentlytaggedSmac-1FandXIAPcontainingbothBIR2andBIR3domains,wehavedeveloped anew,sensitive,androbustFP-basedcompetitivebinding assay. Using this assay, we determined that a previously publishedbivalentSmacmimeticbindstoXIAPcontaining bothBIR2andBIR3domainswithaKivalueoflessthan 1nM,being10,000timesmorepotentthantheAVPIpeptide. Conclusion Thecurrentstudyhasclearlydemonstratedthatbivalent Smac-based ligands bind concurrently to both the BIR2andBIR3domainsoftheXIAPandachievemuch higher aYnities than do the corresponding monovalent Smac-based ligands. Using mutated XIAPs, we showed thatbothBIR2andBIR3inXIAParedirectlyinvolvedin

98

Bivalent Smac-based peptides as antagonists of XIAP / Z. Nikolovska-Coleska et al. / Anal. Biochem. 374 (2008) 87­98 [8] M. Holcik, H. Gibson, R.G. Korneluk, XIAP: Apoptotic brake and promisingtherapeutictarget,Apoptosis6(2001)253­261. [9] E.C.LaCasse,S.Baird,R.G.Korneluk,A.E.MacKenzie,Theinhibitorsofapoptosis(IAPs)andtheiremergingroleincancer,Oncogene 17(1998)3247­3259. [10] S.Fulda,W.Wick,M.Weller,K.M.Debatin,Smacagonistssensitize forApo2L/TRAIL-oranticancerdrug-inducedapoptosisandinduce regressionofmalignantgliomainvivo,Nat.Med.8(2002)808­815. [11] R.Takahashi,Q.Deveraux,I.Tamm,K.Welsh,N.Assa-Munt,S.G. Salvesen,J.C.Reed,AsingleBIRdomainofXIAPsuY ientforinhibc itingcaspases,J.Biol.Chem.273(1998)7787­7790. [12] C.Du,M.Fang,Y.Li,X.Wang,Smac,amitochondrialproteinthat promotescytochromec-dependentcaspaseactivationduringapoptosis,Cell102(2000)33­42. [13] A.M. Verhagen, P.G. Ekert, M. Pakusch, J. Silke, L.M. Connolly, G.E. Reid, R.L. Moritz, R.J. Simpson, D.L. Vaux, Identification of DIABLO,amammalianproteinthatpromotesapoptosisbybinding toandantagonizingIAPproteins,Cell102(2000)43­53. [14] S.M. Srinivasua, R. Hegde, A. Saleh, P. Dat a, E. Shiozaki, J. Chai, l t R.A.Lee,P.D.Robbins,T.Fernandes-Alnemri,Y.Shi,E.S.Alnemri, AconservedXIAP-interactionmotifincaspase-9andSmac/DIABLO regulatescaspaseactivityandapoptosis,Nature410(2001)112­116. [15] J.Chai,C.Du,J.W.Wu,S.Kyin,X.Wang,Y.Shi,StructuralandbiochemicalbasisofapoptoticactivationbySmac/DIABLO,Nature406 (2000)855­862. [16] G.Wu,J.Chai,T.L.Suber,J.W.Wu,C.Du,X.Wang,Y.Shi,StructuralbasisofIAPrecognitionbySmac/DIABLO,Nature408(2000) 1008­1112. [17] Y.Huang,R.L.Rich,D.G.Myszka,H.Wu,Requirementofboththe secondandthirdBIRdomainsforthereliefofX-linkedinhibitorof apoptosis protein (XIAP)-mediated caspase inhibition by Smac, J. Biol.Chem.278(2003)49517­49522. [18] H.Sun,Z.Nikolovska-Coleska,C.Y.Yang,L.Xu,M.Liu,Y.Tomita, H.Pan,Y.Yoshioka,K.Krajewski,P.P.Roller,S.Wang,Structurebaseddesignofpotent,conformationallyconstrainedSmacmimetics, J.Am.Chem.Soc.126(2004)16686­16687. [19] L.Li,R.M.Thomas,H.Suzuki,J.K.DeBrabander,X.Wang,P.G.Harran, A small molecule Smac mimic potentiates TRAIL- and TNFamediatedcelldeath,Science305(2004)1471­1474. [20] A.D. Schimmer, K. Welsh, C. Pinilla, Z. Wang, M. Krajewska, M.J. Bonneau, I.M. Pedersen, S. Kitada, F.L. Scott, B. Bailly-Maitre, G. Glinsky,D.Scudiero,E.Sausville,G.Salvesen,A.Nefzi,J.M.Ostresh, R.A. Houghten, J.C. Reed, Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity, Cancer Cell 5 (2004)25­35. [21] K.Zobel,L.Wang,E.Varfolo eev,M.C.Franklin,L.O.Elliott,H.J. m Wall eber,D.C.Okawa,J.A.Flyg re,D.Vucic,W.J.Fairbrother,K. w a Deshayes,Design,synthesis,andbiologicalactivityofapotentSmac mimeticthatsensitizescancercellstoapoptosisbyantagonizingIAPs, ACSChem.Biol.1(2006)525­533. [22] Z.Nikolovska-Coleska,R.Wang,X.Fang,H.Pan,Y.Tomita,P.Li, P.P.Roller,K.Krajewski,N.G.Saito,J.A.Stuckey,S.Wang,DevelopmentandoptimizationofabindingassayfortheXIAPBIR3domain usingfluorescencepolarization,Anal.Biochem.332(2004)261­273. [23] R.A.Kipp,M.A.Case,A.D.Wist,C.M.Cresson,M.Carrell,E.Griner,A.Wita,P.A.Albiniak,J.Chai,Y.Shi,M.F.Semmelhack,G.L. i McLendon, Molecular targeting of inhibitor of apoptosis proteins basedonsmallmoleculemimicsofnaturalbindingpartners,Biochemistry41(2002)7344­7349.

theinteractionwithbivalentSmac-basedligands.Bivalent Smac-basedligandsarealsomuchmorepotentantagonists ofXIAPthanthecorrespondingmonovalentSmac-based ligandsincell-freecaspasefunctionalassays.Hence,bivalentSmac-basedpeptideligandsmimicthemodeofaction of the mature dimeric Smac protein in interaction with XIAP.UsingthefluorescentlytaggedSmac-1FandXIAP containing both BIR2 and BIR3 domains, we developed a new, sensitive, and robust FP-based competitive bindingassayandshowedthatourdesignedbivalentSmac-1 and a previously published bivalent Smac mimetic bind to XIAP containing both BIR2 and BIR3 domains with aYnities1000timeshigherthantheSmacAVPIpeptide. Taken together, the current results provide new insights intothemodeofactionofbivalentSmacligandsagainst XIAPandabasisforthedesignanddevelopmentofcellpermeable,bivalentSmacmimet csaspowerfulpharmai cological tools and potentially useful therapeutic agents. The results on the design and characterization of new, cell-permeable, bivalent Smac mimetics will be reported induecourse. Acknowledgments We are grateful for financial support from the Breast CancerResearchFoundation,theProstateCancerFoundation,theDepartmentofDefenseCongressionallyDirected Medical Research Programs (W81XWH-04-1-0213), and theNationalCancerInstitute,NationalInstitutesofHealth (R01CA109025).WethankG.W.A.Milneforhiscritical readingofthemanuscript. References
[1] D.W.Nicholson,Frombenchtoclinicwithapoptosis-basedtherapeuticagents,Nature407(2000)810­816. [2] S.W. Lowe, A.W. Lin, Apptosis in cancer, Carcinogenesis 21 (2000) 485­495. [3] B.A.Ponder,Cancergenetics,Nature411(2001)336­341. [4] G.S.Salvesen,C.S.Duckett,IAPproteins:Blockingtheroadtodeath's door,Nat.Rev.Mol.CellBiol.3(2002)401­410. [5] Q.L.Deveraux,E.Leo,H.R.Stennicke,K.Welsh,G.S.Salvesen,J.C. Reed,CleavageofhumaninhibitorofapoptosisproteinXIAPresults infragmentswithdistinctspecificitiesforcaspases,EMBOJ.18(1999) 5242­5251. [6] C.Sun,M.Cai,R.P.Meadows,N.Xu,A.H.Gunaseker ,J.Herrmann, a J.C.Wu,S.W.Fesik,NMRstructureandmutagenesisofthethirdBir domainoftheinhibitorofapoptosisproteinXIAP,J.Biol.Chem.275 (2000)33777­33781. [7] F.L.Scott,J.B.Denault,S.J.Riedl,H.Shin,M.Renatus,G.S.Salvesen, XIAPinhibitscaspase-3and-7usingtwobindingsites:Evolutionarily conservedmechanismofIAPs,EMBOJ.24(2005)645­655.

